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ABSTRACT
Background. The new 7th edition of the Union for Interna-
tional Cancer Control–American Joint Committee on Cancer
(UICC-AJCC) tumor, node, metastasis (TNM) staging system
is the ratification of data-driven recommendations from the
Worldwide Esophageal Cancer Collaboration database. Gen-
eralizability remains questionable for single institutions. The
present study serves as a validation of the 7th edition of the
TNM system in a prospective cohort of patients with pre-
dominantly adenocarcinomas from a single institution.
Methods. Included were patients who underwent transhi-
atal esophagectomy with curative intent between 1991 and
2008 for invasive carcinoma of the esophagus or gastro-
esophageal junction. Excluded were patients who had
received neoadjuvant chemo(radio)therapy, patients after a
noncurative resection and patients who died in the hospital.
Tumors were staged according to both the 6th and the 7th
editions of the UICC-AJCC staging systems. Survival was
calculated by the Kaplan–Meier method, and multivariate
analysis was performed with a Cox regression model. The
likelihood ratio chi-square test related to the Cox regres-
sion model and the Akaike information criterion were used
for measuring goodness of fit.
Results. A study population of 358 patients was identified.
All patients underwent transhiatal esophagectomy for ade-
nocarcinoma. Overall 5-year survival rate was 38%.
Univariate analysis revealed that pT stage, pN stage, and
pM stage significantly predicted overall survival. Prediction
was best for the 7th edition, stratifying for all substages.
Conclusions. The application of the 7th UICC-AJCC
staging system results in a better prognostic stratification of
overall survival compared to the 6th edition. The fact that
the 7th edition performs better predominantly in patients
with adenocarcinomas who underwent a transhiatal surgi-
cal approach, in addition to findings from earlier research
in other cohorts, supports its generalizability for different
esophageal cancer practices.
Accurate staging of cancer is important for stage-specific
treatment, thus minimizing inappropriate treatment. More-
over, it allows for interinstitutional comparisons and
disclosure of prognosis to patients.1 The staging system for
cancer in the esophagus and esophagogastric junction has
been revised as outlined in the 7th edition of the Union for
International Cancer Control/Union Internationale Contre
le Cancer (UICC) and the American Joint Committee on
Cancer (AJCC), Cancer Staging Manual.2
Retrospective studies suggested that the number of
involved lymph nodes is a better predictor of outcome than
classifying lymph node involvement as either present or
absent.3,4 Peyre et al. showed that patients with C3 lymph
nodes involved have a risk of systemic disease that exceeds
50%. When[8 nodes are involved, the risk of dying is almost
100%.5 Indeed, the latest 7th edition of the UICC-AJCC
esophageal tumor, node, metastasis (TNM) staging system
has acknowledged the importance of the number of involved
nodes by revising the N category from site-dependent staging
to a numerically based classification into N0 to N3. Another
major change is the definition of regional lymph nodes.
The new UICC-AJCC staging system is the ratification
of data-driven recommendations from a database of[7800
esophageal cancer patients created from a large multi-
institutional collaboration involving 13 institutions.6,7 This
Worldwide Esophageal Cancer Collaboration (WECC)
database overcomes problems of rarity of this cancer, but
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generalizability remains questionable for single institu-
tions. WECC incorporates high-volume centers both from
the West (where adenocarcinomas prevail) and from the
East (where most tumors are squamous cell carcinomas).
Moreover, the extent of intrathoracic lymph node dissec-
tion can vary greatly between different institutions, leading
to potential bias.
The present study serves as a validation of the WECC-
based 7th edition of the TNM system in a cohort of patients
with both squamous cell carcinomas and adenocarcinomas
from a single Western high-volume institution. Two studies
already showed that the 7th edition criteria resulted in better
prognostic stratification than the 6th edition.8,9 However,
both study cohorts consisted of squamous cell carcinomas
or junctional tumors, respectively. Moreover, Gaur et al.
included patients who received (neo)adjuvant therapy.9
The aim of this study was to assess the predictive ability
of the 7th edition of the AJCC TNM staging system for
overall survival and to compare this with the 6th edition in a
cohort of patients who underwent transhiatal esophagec-
tomy for adenocarcinomas without (neo)adjuvant therapy.
PATIENTS AND METHODS
Study Population
Included were all patients who underwent a transhiatal
esophagectomy with curative intent between January 1991
and September 2008 at the Erasmus Medical Center
(Rotterdam, The Netherlands) for invasive squamous cell
carcinoma and adenocarcinoma of the esophagus or gas-
troesophageal junction. Excluded were patients who had
received neoadjuvant chemo(radio)therapy, patients after a
noncurative (R1) resection (tumor-free margin\1 mm) and
patients who died in the hospital. Clinicopathologic data of
all patients had been routinely collected in an ongoing
prospective registry.
Surgery
Transhiatal esophagectomy with cervical anastomosis
was the chosen surgical approach in the present study. This
encompasses the en-bloc dissection of the primary tumor
and its adjacent lymph nodes under direct vision through
the widened hiatus of the diaphragm up to the level of the
inferior pulmonary vein. Subsequently, a 3–4-cm-wide
gastric tube is created. The left gastric artery is transected
at its origin with resection of celiac trunk lymph nodes.
After mobilization and transection of the cervical esopha-
gus, the intrathoracic middle and upper esophagus is
bluntly dissected in an antegrade fashion with a vein
stripper. Esophagogastrostomy is performed in the neck
without a formal cervical lymphadenectomy.
Follow-up
Surviving patients were followed at regular intervals at
the outpatient clinic until 5 years after surgery. Outpatient
clinic visits encompassed history taking and physical
examination. No routine imaging was performed. Recur-
rences were sought afterward, only when clinically
indicated, by CT scan or ultrasound and proven by histol-
ogy and cytology whenever possible. Overall survival was
defined as the time between date of operation and date of
death. Surviving patients were censored on the day of last
follow-up. Patient survival status was calculated after
contacting the general practitioners (performed by a trained
data manager). The last follow-up checkpoint was July
2010. If follow-up was incomplete, survival was verified in
the municipal mortality registers.
Statistical Analysis
Tumors were staged according to both the 6th and 7th
editions of the UICC-AJCC staging systems. Survival was
calculated by the Kaplan–Meier method, and differences
between curves were assessed by the log rank test.
Two multivariable models were built, one with the 6th
edition and one with the 7th edition of the TNM staging
system as categorical variables. The performance was
tested for the model in which the stages were combined
into four categories (I–IV) as well as for the model with all
substages included (IA, IB, IIA, IIB, IIIA, IIIB, IIIC, IV).
A multivariable model with both 6th and 7th edition cri-
teria included was used to assess the remaining value of the
6th edition when the 7th edition information was known.
The likelihood ratio chi-square test related to the Cox
regression model was used for measuring goodness of fit.
The Akaike information criterion (AIC) was applied to
correct for the potential bias in comparing prognostic
systems with different number of stages.10,11 The -2 log
likelihood (which is the parameter in the Cox regression) of
the 6th edition was compared to that of the 7th edition; the
smaller the value of this statistic, the better the model.
AIC was defined as: AIC = -2 log maximum likeli-
hood ? 2 9 (the number of parameters in the model). A
smaller AIC value indicates a more desirable model for
predicting outcome. A value of P \ 0.05 was considered
statistically significant. Statistical analysis was performed
with SPSS 10 for Windows (SPSS, Chicago, IL).
RESULTS
Patient Characteristics
A consecutive series of 766 patients underwent esopha-
gectomy with curative intent. In total, 221 patients were
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excluded because they had received neoadjuvant
chemo(radio)therapy in the context of a randomized, con-
trolled trial.12 Another 165 patients were excluded because of
a noncurative (R1) resection, and 20 patients were excluded
because of in-hospital mortality. Two patients had an in situ
carcinoma and were also excluded from the current analysis.
This resulted in a final study population of 358 patients.
Mean follow-up was 51 months (median 37 months).
Overall 5-year survival rate was 38%. Most recurrences of
disease occurred within 2 years after surgery.
Patient characteristics and overall survival rates are
summarized in Table 1. All patients underwent transhiatal
esophagectomy for adenocarcinoma. Eight patients seemed
to have distant metastasis during the operation; their dis-
ease was scored as M1.
Univariate analysis revealed that parameters pT stage,
pN stage, and pM stage all significantly predicted overall
survival. Except for histologic grade, no other significant
predictors of survival were detected in this univariate
analysis. The median number of dissected nodes per patient
was 11. In patients with negative lymph nodes (pN0), the
survival rates did not differ between patients with B11
nodes and[11 nodes dissected: 65% vs. 69%, respectively;
P = 0.65; data not shown).
Stratification of Prognosis According to 6th and 7th
Editions of TNM Staging Systems
The overall survival curves according to the N classifi-
cations of the 6th and 7th editions are shown in Fig. 1a and
b, respectively.
Patient stage migration for reclassifying patients from
the 6th to the 7th staging system and their survival rates are
listed in Table 2. In 58% of the 358 esophageal cancer
patients, stage did not differ in these two classification
systems. Reassignment of disease stage occurred in all
other patients, either to a higher or to a lower tier.
According to the 6th edition staging system, 56 (87%) of
64 stage IV patients were staged as such because of a celiac
lymph node metastasis. These patients were reclassified to
a lower tier in the 7th edition: 6 of 64 were staged as stage
IIB, 15 as stage IIIA, 19 as IIIB, and 16 as IIIC (Table 2).
The Kaplan–Meier curves of esophageal cancer patients
based on the 6th and 7th editions of the TNM staging
systems are depicted in Fig. 2. Both systems show a rela-
tively ordered monotone distribution of survival. However,
according to the 6th edition staging system, the Kaplan–
Meier plot shows overlapping curves for stage III and IV.
In the 7th edition, no important overlapping occurs among
stages I through IV.
Subgroup analysis among selected patients who had
been considered to have stage IV disease acording to the
UICC-AJCC 6th edition scoring system showed that
patients reclassified from stage IV disease to a lower tier in
the UICC-AJCC 7th edition had a significantly better sur-
vival compared to patients still classified as stage IV
according to the UICC-AJCC 7th edition. Moreover, the
UICC-AJCC 7th edition was able to make further signifi-
cant stratification of survival rates of these reclassified
patients (Fig. 3; log rank P = 0.43).
The UICC-AJCC 7th edition staging system defines
patients with positive paraesophageal cervical lymph nodes
(n = 10) as having stage IIIA or IIIB disease. These patients,
however, had a prognosis as bad as that of patients with
distant metastasis (1-year overall survival rate 30% vs. 33%).
TABLE 1 Patient demographics and results of univariate analysis for overall
survival (N = 358)
Characteristic Value 5-y survival,
%
P
No. of patients 358
Age, year,
mean (range)
62.6 (28–83) 38.8
Gender
Male 293 (82%) 37.2 0.664
Female 65 (18%) 45.9
pT
1 78 (22%) 68.7 \0.001
2 79 (22%) 51.1 \0.001
3 201 (56%) 22.7
pN
0 146 (41%) 65.9 \0.001
1 90 (25%) 28.4 \0.001
2 81 (23%) 17.5 \0.001
3 41 (11%) 3.0
pM
0 350 39.7 \0.001
1 8 0.0
Grade
Well differentiated (G1) 31 (9%) 75.3 \0.001
Moderately differentiated (G2) 177 (49%) 39.4 \0.053
Poorly differentiated (G3) 150 (42%) 30.9
Histology
Squamous cell carcinoma 47 (13%) 41.9 0.752
Adenocarcinoma 311 (87%) 38.3
Location
Upper third 6 (2%) 30.4 0.352
Middle third 14 (4%) 42.6 0.325
Lower third (distal ? EGJ) 338 (94%) 36.9
Type of surgical approach
Transhiatal esophagectomy 358 (100%)
Transthoracic esophagectomy
T tumor stage (depth of invasion), N lymphatic dissemination stage (according
to 7th edition of UICC-AJCC TNM staging system: N0 no positive lymph
nodes, N1 1–2 positive lymph nodes, N2 3–6 positive lymph nodes, N3 C6
positive lymph nodes), M distant metastasis stage (according to 7th edition of
UICC-AJCC TNM staging system: M0 no metastasis, M1 distant metastasis
present), EGJ esophagogastric junction
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The performance of the 6th and 7th edition staging
systems won quantified by the likelihood ratio chi-square
and AIC (Table 3). Predictive ability was best for the full
7th edition criteria stratifying for all substages (highest
likelihood ratio v2). AIC value was smaller for the 7th
edition compared to the 6th edition staging system, indi-
cating that it has a better prognostic stratification. The AIC
value was lowest when patients with cervical lymph node
metastasis at a large distance from the primary tumor (i.e.,
the lower third of the esophagus) were also classified as
having stage IV disease. When the 6th and 7th edition
staging systems are both included in one Cox regression
model, the 6th edition no longer significantly predicted
survival, whereas the 7th edition remained a significant
stratifier of prognosis (data not shown).
DISCUSSION
This study shows that both the 6th and 7th UICC-AJCC
TNM staging systems have a distinctive and monotone
(ordered) relationship of stage group to overall survival for
esophageal cancer patients who have undergone potentially
curative surgery without (neo)adjuvant therapy. Distribu-
tion of patients among different stages is in line with that
a bFIG. 1 Kaplan–Meier overall
survival curves for 358 patients
stratified by N stage according
to a 7th edition and b 6th
edition UICC-AJCC TNM
staging systems (overall log
rank P \ 0.01)
TABLE 2 Cross table of staging esophageal cancer patients according to the 6th and 7th editions of UICC-AJCC TNM staging
6th editiona 5 year-survival
according to
7th edition (%)I IIA IIB III IV
7th editionb
IA 43 0 0 0 0 87.7
IB 13 28 0 0 0 73.3
IIA 0 19 0 0 0 55.3
IIB 0 41 24 0 6 40.1
IIIA 0 0 21 50 15 24.3
IIIB 0 0 0 31 19 11.9
IIIC 0 0 4 20 16 3.1
IV 0 0 0 0 8 0.0
5 year-survival according
to 6th edition (%)
81.9 56.8 38.3 14.1 12.4
M1a celiac nodes involved in lower esophageal cancer or cervical nodes involved in upper esophageal cancer, M1b beyond locoregional node
involvement (i.e., cervical nodes in lower esophageal cancer and celiac nodes in upper esophageal cancer; metastatic involvement of visceral
organs, pleura, peritoneum)
a The 6th edition AJCC-UICC TNM staging system: stage I T1N0, stage IIA T2,3N0, stage IIB T1,2N1, stage III T3N1 or T4N0, stage IVA
TanyNanyM1a, stage IVB TanyNanyM1b. The 7th edition AJCC-UICC TNM staging system (for adenocarcinoma): stage IA T1N0G1,2, stage IB
T1N0G3 or T2N0G1,2, stage IIA T2N0, stage IIB T3N0 or T1,2N1, stage IIIA T4N0 or T3N1 or T1,2N2, stage IIIB T3N2, stage IIIC TanyN3 or T4aN1–3
or T4bNany, stage IV Tany,Nany,M1
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described in the literature. All groups are large enough for
proper statistical analysis, except for stage IIA in the 7th
edition.
Further testing of both systems on the present data
shows that the 7th edition has the best performance because
of the lowest AIC (i.e., a better fit) when Cox regression
models are used. Survival curves stratified according to the
UICC-AJCC 7th edition TNM staging system did not
overlap, which is in contrast to the curves of the 6th edi-
tion. Moreover, further stratification of N stage according
to number of positive lymph nodes in the 7th edition is
indeed valuable, as shown in Fig. 1.
A major change in the new TNM staging system is the
definition of regional lymph nodes. There has always been
debate regarding the prognostic importance of positive
celiac nodes, which were considered distant metastases in
earlier editions.13 In the 6th edition staging system, the
Kaplan–Meier plot showed overlapping curves for stage III
and IV. According to the UICC-AJCC 7th edition, only
patients with distant metastasis can be categorized as
having stage IV disease. In contrast, according to the 6th
edition, most stage IV disease was due to nonregional
celiac lymph node metastasis, whereas stage IIB and III
consisted of regional lymph node metastasis. Hence, 87%
(56 of 64) of the patients with stage IV disease who were
assessed according to the 6th edition criteria were reclas-
sified as having stage IIB, IIIA, IIIB, and IIIC disease
according to 7th edition criteria. Because these stages all
had different survivals (Fig. 3), the present results support
the new concept that it is unnecessary to identify nonre-
gional lymph node metastasis and to label these nodes as
M1A or M1B.
Two previous studies have compared the performance
of 6th with the 7th editions of the TNM staging system
in predicting survival. Hsu et al. evaluated 392 patients
who underwent primary surgical resection through a tri-
incisional approach in Taiwan during 1995–2006.8 In the
other study, nearly two-thirds of the patients received
neoadjuvant therapy.9
Both Hsu et al. and Gaur et al. concluded that the 7th
edition of the staging system was a better model for pre-
dicting outcome.8,9 The most important difference with the
present study is tumor histology; the vast majority of our
a bFIG. 2 Kaplan–Meier curves
of overall survival for 358
patients stratified according to a
6th edition and b 7th edition
UICC-AJCC TNM staging
systems
FIG. 3 Kaplan–Meier overall survival curves for 64 UICC-AJCC
6th stage IV patients who were reclassified according to UICC-AJCC
7th edition TNM staging (log rank P = 0.43)
2146 K. Talsma et al.
patients had an adenocarcinoma, and almost all patients
underwent a transhiatal resection.
The WECC-based 7th edition of the TNM staging sys-
tem was built on data from patients without neoadjuvant
treatment in a squamous cell carcinoma predominant
database. Our sample population from a single institution is
of course small compared with the worldwide esophageal
cancer collaboration database, but the surgical procedures
were highly uniform throughout the entire study period.
The previous studies of Hsu et al. and Gaur et al., as well as
the present study, underline the generalizability of the 7th
edition and make it broadly applicable for daily clinical
practice of esophageal cancer surgery around the world.8,9
The 7th edition of the UICC-AJCC esophageal TNM
staging system has acknowledged the importance of the
number of involved nodes by subdividing the N classifi-
cation into N0 to N3. The transhiatal approach may
profoundly affect the completeness of lymph node dissec-
tion and, accordingly, proper nodal staging. On the basis of
data from a Dutch trial, nowadays, tumors proximal of
esophagogastric junction (Siewert type 1) are preferably
offered a transthoracic approach in our institution.14,15 The
latter approach will result in the collection of more lymph
nodes and might give a more valid node sampling for
staging. To which extent lymph nodes should be sampled
for proper staging remains an important issue.16 In a study
performed by Peyre et al., the number of lymph nodes
removed was an independent predictor of survival and a
minimum number of 23 regional lymph nodes was pro-
posed.17 In the present study, the median number of nodes
removed in a transhiatal approach was 11. This relatively
scarce lymph node collection result can be seen as a
drawback of our study, but it also gives rise to a remarkable
finding. Although all patients underwent a transhiatal
esophagectomy, the survival curves of different N stages
(N0–N3; Fig. 1) do not overlap in our data, which probably
indicates that there has been a valid and robust node
sampling. On the other hand, there seems to be a relatively
large difference in survival rate between N0 and N1. We
know from previous studies that there is a dichotomy in
survival rate between tumors that did and did not lym-
phatically disseminate.18 Early tumors (pT1) with lymph
node invasion have prognosis comparable to tumors with
more advanced T stage. Lymphatic dissemination is an
independent indication of the biological aggressiveness of
the tumor.
However, the large step in survival rate between N0 and
N1 might also be due to a stage migrational effect. This,
the so-called Will Rogers effect, means that stage N1
disease might actually include N2 or even N3 disease as a
result of invalid node sampling.19 The WECC group has
indicated a resection of a minimum of 10 nodes for T1, 20
for T2, and C30 nodes for T3–4 to be resected to obtain
optimal results.20 In N0 patients, such an effect does not
occur; we found no significant difference in survival rates
according to the number of resected lymph nodes in lymph
node–negative patients. However, a median of 11 nodes
definitely entails the risk of a stage migration effect in the
patient group with positive nodes.
Finally, an important question remains: does a better
predictive staging system have consequences for preoper-
ative decision making? Medical decision making in terms
of administering neoadjuvant chemotherapy and choosing
the optimal surgical approach for esophagectomy is often
based on clinical N staging. Lack of accurate preoperative
staging is a major problem in allocating treatment modal-
ities in these patients. It has been recently shown that
further stratification according to the position of the posi-
tive node relative to the diaphragm can effectively
discriminate between node-positive patients.21 The overall
accuracy for endoscopic ultrasound and CT in predicting
the N stage per station is moderate, however. When the
therapeutic approach depends on the status of a specific
lymph node station, a more objective and reliable assess-
ment of lymph nodal involvement (e.g., endoscopic
ultrasound–fine-needle aspiration) should be considered.22
This study indicates that the application of the 7th
UICC-AJCC staging system results in a better prognostic
stratification of overall survival compared to the 6th edi-
tion. The fact that the 7th edition also has a superior
prognostic ability in this study population from a single
high-volume institution with predominantly adenocarcino-
mas and a two-incisional surgical approach supports its
generalizability for different esophageal cancer practices.
TABLE 3 Prognostic stratification of the 6th and 7th editions of the UICC-AJCC TNM staging systems
Model Figure Subgroups LR v2 AIC valuea
6th edition 2a I, II, III, IV 96.9 2607.1
7th edition, full 2b IA, IB, IIA, IIB, IIIA, IIIB, IIIC, IV 128.6 2592.9
7th edition, collapsed I, II, III, IV 99.0 2605.4
AIC Akaike information criteria, LR likelihood ratio
a A lower AIC value represents a better discriminatory model
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